Elizabeth Laws has been appointed to lead the KT-621 development program, which is advancing as a first-in-class oral small molecule degrader, involving Sanofi and Kymera Therapeutics.
1 report, 1 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Elizabeth Laws has been appointed to lead the KT-621 development program, which is advancing as a first-in-class oral small molecule degrader, involving Sanofi and Kymera Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sanofi
company in Milan, Italy
Nothing else this week.